Home Newsfeeds Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Goldman Sachs analyst Corinne Jenkins initiates coverage on Altimmune (NASDAQ:ALT) with a Buy rating and announces Price Target of $20.

byBenzinga Newsdesk

December 1, 2022

1 minute read

Goldman Sachs analyst Corinne Jenkins initiates coverage on Altimmune (NASDAQ:ALT) with a Buy rating and announces Price Target of $20.

MEI Pharma Announces 1-For-20 Reverse Stock Split

By Happy Mohamed

April 15, 1:17 AM

MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved a 1-for-20 reverse stock split. The

MEIP

McKesson Earnings Are Imminent; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

By Avi Kapoor

February 7, 11:04 AM

McKesson Corporation (NYSE: MCK) is expected to release earnings results for its third quarter, after the closing bell on Feb. 7, 2024.

MCK

Jim Cramer Calls This Key Apple Supplier ‘A Great Company’ After Stock Closed Nearly 5% Higher

By Benzinga Neuro

February 8, 2:25 AM

This endorsement from Cramer comes at a time when Taiwan Semiconductor is making significant moves in the industry.

TSM

HP, Jabil And This Industrial Stock Insiders Are Selling

By Lisa Levin

February 3, 2:22 PM

The Nasdaq dropped by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades.

HPQ

Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20

Related Posts

MEI Pharma Announces 1-For-20 Reverse Stock Split

McKesson Earnings Are Imminent; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

Jim Cramer Calls This Key Apple Supplier ‘A Great Company’ After Stock Closed Nearly 5% Higher

HP, Jabil And This Industrial Stock Insiders Are Selling